1245708-13-7 Usage
Uses
Used in Pharmaceutical Industry:
6-Bromo-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one is used as an OGA inhibitor for the development of therapeutic agents to treat various diseases. By modulating the activity of OGA, 6-Bromo-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one can potentially influence cellular processes and pathways that are implicated in the progression of certain diseases, offering a novel approach to treatment.
Used in Research Applications:
In addition to its pharmaceutical applications, 6-Bromo-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one can be utilized in research settings to study the role of O-GlcNAcylation in cellular function and disease mechanisms. 6-Bromo-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one can serve as a valuable tool for investigating the impact of OGA inhibition on cellular signaling, protein function, and the development of new therapeutic strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 1245708-13-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,4,5,7,0 and 8 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1245708-13:
(9*1)+(8*2)+(7*4)+(6*5)+(5*7)+(4*0)+(3*8)+(2*1)+(1*3)=147
147 % 10 = 7
So 1245708-13-7 is a valid CAS Registry Number.
1245708-13-7Relevant academic research and scientific papers
HETEROCYCLIC COMPOUNDS WITH AN ROR(GAMMA)T MODULATING ACTIVITY
-
Paragraph 0650, (2018/03/06)
The present invention relates to a compound that may have an ROR(gamma)t modulating activity and can thus be useful in the treatment of cancer.
Development of novel benzomorpholine class of diacylglycerol acyltransferase i inhibitors
Zhou, Gang,Zorn, Nicolas,Ting, Pauline,Aslanian, Robert,Lin, Mingxiang,Cook, John,Lachowicz, Jean,Lin, Albert,Smith, Michelle,Hwa, Joyce,Van Heek, Margaret,Walker, Scott
supporting information, p. 544 - 549 (2014/06/09)
Diacylglycerol acyltransferase 1 (DGAT1) presents itself as a potential therapeutic target for obesity and diabetes for its important role in triglyceride biosynthesis. Herein we report the rational design of a novel class of DGAT1 inhibitors featuring a
